Post-transplant dental cleaning to prevent chronic graft-versus-host disease
Official title: Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease
Run by Fred Hutchinson Cancer Center · NCT07535008 · Data updated 2026-11-12
This will try a dental cleaning about 28 days after an allogeneic stem cell transplant to see if it lowers the chance of chronic graft-versus-host disease in adult transplant recipients.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 45 (estimated) |
| Sponsor | Fred Hutchinson Cancer Center Academic / other |
| Drugs / interventions | ruxolitinib, cyclophosphamide |
| Locations | 1 site (Seattle, Washington) |
| Status | Recruiting |
| Started | May 12, 2026 |
| Main results expected | April 30, 2028 |
| Study ends | April 30, 2029 |
| Registry record updated | October 21, 2026 |
| Trial ID | NCT07535008 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) receiving a T-replete allogeneic hematopoietic cell transplant from a 9/10 or 10/10 matched unrelated donor or cord blood who have natural teeth and can attend in-person follow-up at Fred Hutch are the ideal candidates.
✕Probably not a fit
Patients without teeth (edentulous), those receiving bone marrow grafts, or those treated with post-transplant cyclophosphamide, ruxolitinib, or ATG are excluded and unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults undergoing T-replete allogeneic hematopoietic cell transplant will receive a baseline dental cleaning if they have not had one within three months, and all participants will undergo a simplified dental cleaning on day +28 after transplant with dental plaque sampling. The study collects plaque samples and monitors participants for signs of chronic GVHD at days +84, +180, and at one year, including an in-person oral medicine visit at Fred Hutch. Key exclusions include edentulous patients, bone marrow graft source, and use of post-transplant cyclophosphamide, ruxolitinib, or anti-thymocyte globulin in conditioning. The approach tests whether altering early post-transplant oral bacterial burden by an additional cleaning affects later chronic GVHD risk.
Why it matters
Potential benefit: If successful, adding an early post-transplant dental cleaning could lower the risk of chronic GVHD and improve long-term oral health and quality of life after allogeneic HCT.
How similar studies have gone: Preliminary research indicates the post-transplant oral microbiome may influence chronic GVHD, but using a specific post-transplant dental cleaning as a preventive measure is a relatively novel and unproven approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years old * T-replete allogeneic hematopoietic cell transplantation for any indication. History of prior transplantation is allowed. Any conditioning regimen is allowed * One of the following HCT donor types: * 9/10 or 10/10 human leukocyte antigen (HLA)-matched unrelated donor * Cord blood * Willing to have an in-person 1-year long-term follow-up (LTFU) visit including an oral medicine at Fred Hutch (FH) * Ability to understand and sign a written informed consent document (or legal representative) Exclusion Criteria: * Edentulous state * Bone marrow as graft source * Use of post-transplantation cyclophosphamide (PTCy) or ruxolitinib as GVHD prophylaxis * Use of anti-thymocyte globulin (ATG) in conditioning
Where it's running
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States Recruiting
Study contacts
- Principal investigator: Armin Rashidi, MD, PhD — Fred Hutch/University of Washington Cancer Consortium
- Study coordinator: Armin Rashidi, MD, PhD
- Email: arashidi@fredhutch.org
- Phone: 206-667-2506
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Mindfulness program to help with symptoms in chronic graft-versus-host disease
A mindfulness-based program is being tested to see if it can reduce patient-reported symptoms for adults with chronic graft-versus-host disease after a stem cell transplant.
-
See if virtual informed consent methods help people decide to join cancer research
This trial tests whether virtual human communicators and different consent messages can influence cancer patients’ understanding and willingness to participate in research.
-
AI-powered supportive care chatbot for young adult cancer survivors
A chatbot driven by artificial intelligence is tested to help young adult cancer survivors manage symptoms and care needs after treatment.
-
Belumosudil vs Best Available Therapy for chronic graft-versus-host disease
In people aged 12 and up with chronic graft-versus-host disease, the study tests belumosudil to see if it works better than the doctor’s choice of best available therapy after prior treatments have failed.
-
Telehealth pharmacist-led opioid education for cancer patients
This pilot tests a telehealth group education session led by a palliative care pharmacist to help adults with cancer use opioids more safely and effectively.
-
Non-invasive brain stimulation to help chemotherapy-induced nerve problems in cancer survivors
This trial tests whether a gentle brain stimulation method (tDCS) can help reduce numbness, tingling, and pain from CIPN in cancer survivors who are not currently in treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.